MedPath

Dexpanthenol

Generic Name
Dexpanthenol
Brand Names
Fortaplex, Infuvite, Infuvite Pediatric, Mvi Pediatric, Neo-bex
Drug Type
Small Molecule
Chemical Formula
C9H19NO4
CAS Number
81-13-0
Unique Ingredient Identifier
1O6C93RI7Z

Overview

Dexpanthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Dexpanthenol is enzymatically cleaved to form pantothenic acid, which is an essential component of Coenzyme A, which acts as a cofactor in many enzymatic reactions that are important for protein metabolism in the epithelium. Due to its good penetration and high local concentrations, dexpanthanol is used in many topical products, such as ointments and lotions for treatment of dermatological conditions to relieve itching or promote healing. Dermatological effects of the topical use of dexpanthenol include increased fibroblast proliferation and accelerated re-epithelialization in wound healing. Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties . Dexpanthenol is also available as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol) as Panthenol. While pantothenic acid is optically active, only the dextrorotatory form (dexpanthenol) is biologically active.

Background

Dexpanthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Dexpanthenol is enzymatically cleaved to form pantothenic acid, which is an essential component of Coenzyme A, which acts as a cofactor in many enzymatic reactions that are important for protein metabolism in the epithelium. Due to its good penetration and high local concentrations, dexpanthanol is used in many topical products, such as ointments and lotions for treatment of dermatological conditions to relieve itching or promote healing. Dermatological effects of the topical use of dexpanthenol include increased fibroblast proliferation and accelerated re-epithelialization in wound healing. Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties . Dexpanthenol is also available as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol) as Panthenol. While pantothenic acid is optically active, only the dextrorotatory form (dexpanthenol) is biologically active.

Indication

Injection: Prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus. Intestinal atony causing abdominal distention; postoperative or postpartum retention of flatus, or postoperative delay in resumption of intestinal motility; paralytic ileus. Topical: This medication is used as a moisturizer to treat or prevent dry, rough, scaly, itchy skin and minor skin irritations (e.g., diaper rash, skin burns from radiation therapy).

Associated Conditions

  • Allergic Rhinitis (AR)
  • Bursitis
  • Canker Sore
  • Contusions
  • Dermabrasion
  • Diaper Rash
  • Dry Skin
  • Edema
  • Hoarseness
  • Inflammation
  • Inflammation of Mouth
  • Insect Bites
  • Lateral Epicondylitis
  • Lesions of the Mucous Membranes
  • Nasal Congestion
  • Pharyngeal inflammation
  • Pruritus
  • Respiratory Tract Infections (RTI)
  • Seasonal Allergic Rhinitis
  • Sinusitis
  • Skin Roughness
  • Sore Throat
  • Sunburn
  • Tendinitis
  • Tooth Extraction Site Healing
  • Traumatic Injuries caused by Dental Prosthesis
  • Urticaria
  • Vitamin Deficiency
  • Wounds caused by Surgery, Oral of the Tonsils
  • Dry, cracked skin
  • Dryness of the nose
  • Superficial Conjunctival injuries
  • Superficial Corneal injuries
  • Superficial Traumatic Injuries of the Nasal Mucosa
  • Superficial Wounds

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Sandoz Inc
54643-9023
INTRAVENOUS
5 mg in 5 mL
10/28/2016
Sandoz Inc
54643-9015
INTRAVENOUS
15 mg in 10 mL
10/28/2016
Dr. Donna Restivo DC
62185-0059
ORAL
6 [hp_X] in 1 mL
5/23/2025
Carilion Materials Management
68151-1928
ORAL
5 mg in 1 1
11/11/2013
Raw Materials International Overseas LLC
69877-026
INTRAMUSCULAR, INTRAVENOUS
2 mg in 1 mL
12/31/2015
Merit Pharmaceutical
30727-300
INTRAMUSCULAR, INTRAVENOUS
2 mg in 1 mL
12/4/2020
Sandoz Inc
54643-7874
INTRAVENOUS
15 mg in 10 mL
10/28/2016
Sandoz Inc
54643-5650
INTRAVENOUS
15 mg in 10 mL
3/17/2016
PureTek Corporation
59088-180
ORAL
15 mg in 1 1
1/11/2023
FLON LABORATORIES LLC
71414-225
INTRAVENOUS, INTRAMUSCULAR
2 mg in 1 mL
9/29/2017

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
TAMIPOOL FOR INJECTION
SIN11849P
INJECTION, POWDER, FOR SOLUTION
15 mg/vial
3/15/2002
CERNEVIT FOR INJECTION
SIN11975P
INJECTION, POWDER, FOR SOLUTION
17.25 mg/vial
6/5/2002
ENZYPLEX TABLET
SIN06211P
ENTERIC COATED TABLET
5 mg
5/3/1991
IBERET-FOLIC-500 TABLET
SIN05447P
TABLET, FILM COATED
10 mg
2/19/1991
SOLUVIT N FOR INFUSION
SIN05209P
INJECTION, POWDER, FOR SOLUTION
16.5mg /vial
11/14/1990

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
CERNEVIT FOR INJ
N/A
N/A
N/A
4/18/2008
CORNEREGEL EYE GEL 50MG/G
N/A
N/A
N/A
7/23/2007
© Copyright 2025. All Rights Reserved by MedPath